Free Trial

Boston Scientific (BSX) Stock Price, News & Analysis

$81.60
+0.23 (+0.28%)
(As of 09/6/2024 ET)
Today's Range
$80.79
â–Ľ
$81.98
50-Day Range
$72.96
â–Ľ
$81.95
52-Week Range
$48.35
â–Ľ
$82.47
Volume
4.62 million shs
Average Volume
6.07 million shs
Market Capitalization
$119.72 billion
P/E Ratio
68.57
Dividend Yield
N/A
Price Target
$85.38

Boston Scientific MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.95 Rating Score
Upside/​Downside
4.6% Upside
$85.38 Price Target
Short Interest
Healthy
0.73% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.02
Upright™ Environmental Score
News Sentiment
0.79mentions of Boston Scientific in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$1.63 M Sold Last Quarter
Proj. Earnings Growth
12.92%
From $2.40 to $2.71 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.51 out of 5 stars

Medical Sector

88th out of 910 stocks

Surgical & Medical Instruments Industry

12th out of 95 stocks

BSX stock logo

About Boston Scientific Stock (NYSE:BSX)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

BSX Stock Price History

BSX Stock News Headlines

The death of Nvidia?
Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.
Buy Rating for Boston Scientific: Positive Trends and Growth Potential Ahead
Boston Scientific (NYSE:BSX) PT Raised to $94.00 at Raymond James
Boston Scientific (NYSE:BSX) Upgraded by StockNews.com to Buy
Boston Scientific (NYSE:BSX) Reaches New 1-Year High on Analyst Upgrade
The death of Nvidia?
Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.
Boston Scientific Shares Rising Higher
Boston Scientific (NYSE:BSX) Sets New 1-Year High at $79.99
Boston Scientific (NYSE:BSX) PT Raised to $86.00 at Barclays
Boston Scientific (NYSE:BSX) Price Target Raised to $92.00
See More Headlines
Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/24/2024
Today
9/07/2024
Next Earnings (Estimated)
10/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
10113710
Employees
48,000
Year Founded
1979

Price Target and Rating

Average Stock Price Target
$85.38
High Stock Price Target
$95.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+4.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.95
Research Coverage
21 Analysts

Profitability

Net Income
$1.59 billion
Pretax Margin
14.07%

Debt

Sales & Book Value

Annual Sales
$15.23 billion
Cash Flow
$2.90 per share
Book Value
$13.99 per share

Miscellaneous

Outstanding Shares
1,467,096,000
Free Float
1,459,761,000
Market Cap
$119.72 billion
Optionable
Optionable
Beta
0.78

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Boston Scientific Co.:

  • Boston Scientific's stock price has been showing a positive trend, reaching $77.58 on the NYSE as of today, indicating potential growth.
  • The company has consistently beaten earnings estimates, with a recent EPS of $0.62 for the quarter, surpassing the consensus estimate by $0.04.
  • Boston Scientific has a strong revenue growth rate, with $4.12 billion in revenue for the last quarter, exceeding analyst expectations.
  • The company has a solid net margin of 12.00% and a return on equity of 16.80%, indicating efficient financial management.
  • Analysts have given Boston Scientific a positive rating, with a majority of analysts recommending a buy or strong buy for the stock.

Cons

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

  • Despite the positive aspects, Boston Scientific's stock price volatility may pose a risk to investors looking for stable returns.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, August 22, 2024. Please send any questions or comments about these Boston Scientific pros and cons to contact@marketbeat.com.

BSX Stock Analysis - Frequently Asked Questions

How have BSX shares performed this year?

Boston Scientific's stock was trading at $57.81 on January 1st, 2024. Since then, BSX stock has increased by 41.2% and is now trading at $81.60.
View the best growth stocks for 2024 here
.

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) announced its earnings results on Wednesday, July, 24th. The medical equipment provider reported $0.62 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.04. The company's revenue for the quarter was up 14.5% compared to the same quarter last year.
Read the conference call transcript
.

What is Michael F. Mahoney's approval rating as Boston Scientific's CEO?

947 employees have rated Boston Scientific Chief Executive Officer Michael F. Mahoney on Glassdoor.com. Michael F. Mahoney has an approval rating of 98% among the company's employees. This puts Michael F. Mahoney in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Does Boston Scientific have any subsidiaries?

Boston Scientific subsidiaries include these companies: VertiFlex, BTG, Augmenix, Veniti, Claret Medical, Cryterion Medical, nVision Medical, and more.

Who are Boston Scientific's major shareholders?

Boston Scientific's top institutional investors include Primecap Management Co. CA (2.59%), Massachusetts Financial Services Co. MA (2.17%), Bank of New York Mellon Corp (1.01%) and Legal & General Group Plc (0.95%). Insiders that own company stock include Michael F Mahoney, Daniel J Brennan, Joseph Michael Fitzgerald, Jeffrey B Mirviss, John Bradley Sorenson, Edward J Ludwig, Edward J Ludwig, Wendy Carruthers, Jonathan Monson, Eric Francis Yves Thepaut, Vance R Brown, Nelda J Connors, Arthur C Butcher, Charles J Dockendorff, Ian T Meredith, Jodi Euerle Eddy, David S Wichmann, David A Pierce and Scott Olson.
View institutional ownership trends
.

How do I buy shares of Boston Scientific?

Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Boston Scientific own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Boston Scientific investors own include NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AT&T (T), CVS Health (CVS), Walt Disney (DIS) and Bank of America (BAC).

This page (NYSE:BSX) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners